This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria | MicrobiomeTrials
← Back to trials NCT06865651
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2025-05-22Est. Completion: 2027-08-23
Enrollment target: 44 participantsLocations Ziaderm Research LLC, North Miami Beach, Florida, United States Endeavor Health, Glenview, Illinois, United States Novartis Investigative Site, Grenoble, France Novartis Investigative Site, Montpellier, France Novartis Investigative Site, Paris, France Novartis Investigative Site, Pierre-Bénite, France Novartis Investigative Site, Dresden, Saxony, Germany Novartis Investigative Site, Berlin, Germany Novartis Investigative Site, Mainz, Germany Novartis Investigative Site, Tübingen, Germany Novartis Investigative Site, Poznan, Poland Novartis Investigative Site, Rzeszów, Poland Novartis Investigative Site, Warsaw, Poland Novartis Investigative Site, Barcelona, Catalonia, Spain Novartis Investigative Site, Pamplona, Navarre, Spain Novartis Investigative Site, Alicante, Spain Novartis Investigative Site, Madrid, Spain Other microbiome trials you might be interested in Chronic Inducible Urticaria Chronic Spontaneous Urticaria
This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinic…
Birmingham, United States Est. completion Dec 31, 2026
Chronic Spontaneous Urticaria Cholinergic Urticaria Cold Urticaria
The purpose of the study is to investigate the mechanism of action for ligelizumab (QGE031) treatment in patients with c…
Berlin, Germany Completed Jul 19, 2022